Dow Jones 10483.07 +16.04 1:25 pm PST, June 7, 2005  NASDAQ 2067.16 -8.60 For info, visit access.smallcapnetwork.com S & P 500 1197.26 -0.25 Change your subscription status here Russell 2000 623.78 +0.84 VOLUME 05: ISSUE 43  Feature: Bio Advances - Biophan, MIV Therapeutics. Stream's Revenue Flows. Biophan (OTCBB: BIPH) CEO Michael Weiner recently stated: "There is no longer any excuse for not making and certifying devices to be safe with MRI machines." And he should know. Biophan now holds 127 issued or pending US patents as well as 46 international patents (issued or pending) improving the safety and efficacy of implantable devices. There is little doubt that Biophan is not only at the forefront of making implantable devices safer for MRI patients, it is the leader in the sector. Mr. Weiner goes on to state that by virtue of Biophan's extensive and growing IP portfolio, it is able to: "...supply manufacturers with a toolkit of solutions to resolve the MRI-safety and image-quality problems inherent in many medical devices, both on the market and on the drawing boards." We continue to suggest that risk-oriented investors should have and accumulate a core BIPH position in their smallcap portfolio. Since we brought BIPH to the readership in December 2003 at 35 cents, the shares, while at times volatile, have performed nicely for investors. Currently $2.80, that represents an 8 times return over that period. We believe that the shares continue to be in an uptrend and could well test and potentially take out the old high of $3.50. There is little doubt that the company has progressed markedly since those initial days and built its vision into a reality. Living with Reality That reality will likely save patient lives. Thanks to Biophan, millions of patients--new, current and future--will eventually, we believe, be able to access life saving MRI tests without the fear of implanted devices either compromising their health or simply precluding them from these critical diagnostic tests. The ongoing R&D of Biophan, coupled with dozens of issued or pending patent clusters means that the big diagnostic device companies will have little choice than to review and, in our opinion, eventually license the company's technology. That of course translates into exciting revenue potential for both the company and its shareholders. Biophan, as with MIV Therapeutics below, is both a technology and demographic play. Certainly the enhanced safety of devices is paramount, but the natural growth of the multi-billion-dollar device market as boomers enter their fifties and sixties will likely deliver unparalleled growth. It's not a matter of if it materializes: the market is already here and will rise exponentially for at least the next two decades. With Biophan's intellectual property portfolio growing monthly, virtually any future device will likely include one of its patented technologies. Do the math. The potential for shareholders is, in our opinion, compelling to say the least. You should really own at least a few shares in the long-term portion of your smallcap portfolio.   And no less compelling, MIV Therapeutics. I have received some emails over the months musing as to whether BIPH and MIV Therapeutics (OTCBB: MIVT) are actually competitors. While they could be classed as constituents of the same space--improving the efficacy of implantable devices--I would stop short of seeing them as competitors. Complementary, perhaps. The technology of MIVT is vast in its potential applications. Its proprietary coating technologies look destined to improve the life, safety and efficacy of implantable devices such as cardiac stents--both bare metal and drug eluting. As well, the recent acquisitions noted in previous articles bring strong R&D in the case of SagaX and state-of-the-art manufacturing with the bolting on of India's Sahajanand Medical Technologies. As well, the potential for licensing opportunities with big medical device companies is about the only crossover MIVT may have with BIPH. We brought you MIVT in March at 34 cents. The shares have moved nicely with a 76 percent move to 60 cents. We believe that the shares are in a good uptrend and could soon take out the old high of 72 cents. As with BIPH, MIVT is a long-term hold. The potential is no less amazing, in our opinion. Risk-oriented investors should begin or continue to accumulate MIVT shares at these levels. We firmly believe that the best is yet to come for MIV Therapeutics. Both companies are demographic plays. Both have the types of technologies that aren't merely interesting, but, in our opinion, could well become the gold standard in the future development of safer, longer lasting implantable devices. MIV's technology is based on a biocompatible coating made from the natural substance hydroxyapatite. This amazing technology has already proven itself in animal trials to delay or eliminate the types of side effects such as inflammation or thrombosis leading to strokes that were characteristic of early stent technology. Micro-layering hydroxyapatite with polymers for the time release of inflammation and restenosis inhibiting drugs will markedly advanced the development of cardiac stents as well as other implantable devices. As well, the AEPD technology brought in courtesy of SagaX will undoubtedly further cut down on the debilitating or deadly strokes that can occur as a result of cardiac implant surgery. A double whammy As a potential cardiac patient--who isn't?--I welcome the technologies of both companies. As an investor, I am excited about the long-term potential both on the development and revenue fronts. Both companies, though still formative to varying degrees seem to have the types of technologies that will be readily accepted and implemented either by themselves or with the muscle of partners with both the industry reach and also very deep pockets. I would suggest that each deserves a place in a portfolio. It, and likely your health, will benefit nicely over the coming months and years.   Stream's Revenue Flows Some decent Q1 numbers from another front, Cable operator Stream Communications (OTCBB: SCNWF). First quarter revenues increased 67-percent to C$1.4 million over the same quarter 2004. The six cable and Internet acquisitions that the company has completed over the last year have borne significant revenue fruit for shareholders. We expect this trend, as well as good revenue growth, to continue through Q2 2005 and beyond. While the shares have been stable right around our April Alert price of 74 cents, we feel that it is only a matter of time before the shares resume a move to the upside. That said, the next week will likely prove whether the shares have indeed put in a decent bottom. Accumulation appears warranted at these levels and on dips. The aggressive and acquisitive approach of the company has already proven to quickly add good shareholder value. Stream is a significant player in a market that is large and in need of its products and services. As the number eight cable provider in Poland in a field of hundreds of companies, we expect Stream to rise up that ladder further and bring significant revenues to shareholders. The experience of cable growth in the US over the last 20 years gives some indication of the buoyancy of both the business model and the potential. Stream is an extremely unique company that should well be of interest to risk-oriented investors.     We Value Your Feedback Got comments, questions or suggestions? Send 'em on over: Editor@smallcapnetwork.com If you wish to send a written request or inquiry, please send it to our physical address: TGR Group, LLC 3525 Del Mar Heights Rd #334 San Diego, CA 92130   Unsubscribe Here D I S C L A I M E R: The SmallCap Digest is an independent electronic publication committed to providing our readers with factual information on selected  publicly traded companies. SmallCap Digest is not a licensed investment professional or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward  maximizing the upside potential for investors while minimizing the downside risk, whenever possible.  Moreover, as detailed below, this publication accepts compensation from third party consultants and/or companies which it features for the publication and circulation of the SmallCap Digest or representation on SmallCapNetwork.net.  Likewise, this newsletter is owned by TGR, LLC.  To the degrees enumerated herein,  this newsletter should not be regarded as an independent publication. Visit Here to view our compensation on every company we have ever covered, or visit the following web address:  http://access.smallcapnetwork.com/compensation_disclosure.html for our full compensation disclosure and http://access.smallcapnetwork.com/short_term_alerts.html for Trading Alerts compensation and disclosure. TGR Group LLC has also been paid a fee of $30,000 by MIV  Therapeutics  for coverage of the company. In addition, TGR Group LLC has been awarded 272,000 warrants with an exercise price of $.26 by Trilogy Capital Partners for coverage of MIV  Therapeutics. TGR Group LLC has been paid a fee of $25,000 in cash and 200,000 newly issued restricted shares from Stream Communications Networks, Inc. for coverage of the company. TGR Group LLC has been paid fees of $65,000 in total directly by Biophan Technologies, Inc. for reporting on the Company. Additionally, TGR Group LLC was paid a fee of $25,000 by Trilogy Capital for reporting on the Company in August of 2004. Additionally, Some of the companies featured in the SmallCap Digest Newsletter pay an ESP (Electronic Service Provider) fee to an affiliated Technology Company for electronic delivery of this newsletter and other web related technology services. Fees range from $3,000 to $5,000 per month. All statements and expressions are the sole  opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities  mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein. From time to time TGR Group LLC sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies. The editor, members of the editor's family, and/or entities with  which the editor is affiliated aside from TGR Group LLC itself, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter. The profiles, critiques, and other editorial content of the SmallCap Digest and SmallCapNetwork.net may contain statements that appear forward as it relates to the expected capabilities of the companies mentioned herein. THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN  SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN  CONSENT OF THE EDITORS OF SMALLCAPNETWORK.NET. We encourage our readers to invest carefully and read the investor information available at the web sites of  the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at  http://www.sec.gov/consumer/cyberfr.htm . Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.